Perceptive Informatics Opens First Customer Care Office in China
BOSTON, Dec. 10, 2012 -- Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation (NASDAQ: PRXL), today announced that it has opened a Customer Care office in Shanghai to service biopharmaceutical researchers in China and Taiwan who are using Perceptive's technology solutions. The launch further strengthens PAREXEL's footprint in Asia and demonstrates its long-term commitment to accelerating drug development in the region.
Perceptive's Customer Care office staff will initially be responsible for supporting clinical studies using ClinPhone® RTSM (randomization and trial supply management) and Datalabs® EDC software and services, and will be the first point of contact for clinical site staff, CRAs and sponsors who have an IVR/IWR system questions on a live study. All Customer Care staff in Shanghai will be bilingual Mandarin/English speakers, with Mandarin being their native first language. The intent is to provide immediate help desk support without any additional need for translation services.
"China has a thriving pharmaceutical and biotechnology industry and is a priority market for many pharmaceutical and biotechnology sponsors. When sponsors work with Perceptive, they can expect high-quality service, locally supported by staff in the region," said George Hunnewell, Corporate Vice President, Operations, Perceptive Informatics. "Through our experience in running hundreds of global clinical trials, we have identified that a robust, native-language help desk is critical to ensuring the smooth and successful implementation of clinical trial technology. This valuable service enables us to meet the evolving needs of our new and existing customers in the rapidly expanding Asian markets."
In addition to the new customer care office in Shanghai, Perceptive has a dedicated team of professionals in Japan located in Tokyo and Kobe to support Japanese investigators, CRAs, and biopharmaceutical clients. Globally, Perceptive customer care is committed to uniform response times and quality, thereby providing seamless issue resolution for all users, irrespective of geography.
About Perceptive Informatics
Perceptive Informatics, a leading eClinical solutions provider and subsidiary of PAREXEL, is focused on helping customers to accelerate the product development process through innovation. Perceptive enables customers to maximize the benefits of clinical trial technologies by providing flexible software-as-a-service (SaaS) applications and leading technology services. The Perceptive Informatics eClinical Suite is built on extensive medical and clinical expertise, as well as a deep understanding of the regulatory environment. The suite includes Randomization and Trial Supply Management (RTSM) technologies, Medical Imaging, Clinical Trial Management Systems (CTMS), Electronic Data Capture (EDC), and Electronic Patient-Reported Outcomes (ePRO). The Perceptive Informatics eClinical Suite blurs the boundaries among systems that traditionally have been used in isolation, resulting in simplified workflow, improved efficiency and enhanced productivity. For more information about the integrated solutions in the Perceptive Informatics eClinical Suite visit www.perceptive.com.
About PAREXEL International
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 70 locations throughout 51 countries around the world, and has approximately 13,330 employees. For more information about PAREXEL International visit www.parexel.com.
This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2012 as filed with the SEC on November 8, 2012, which "Risk Factors" discussion is incorporated by reference in this press release.
The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.